The Quantra® Hemostasis
System: Viscoelastic
Testing for Obstetrics
Because a Mother’s Tomorrow Can’t be Lost Today
Because a Mother’s Tomorrow Can’t be Lost Today
Near Real-Time Hemostasis Data for Obstetrics
The First & Only Viscoelastic Testing System FDA-Cleared for Peripartum Obstetric Procedures
Challenging Deliveries Need Clear, Accurate, and Timely Data
Hemorrhage during childbirth can’t afford to wait.
In the midst of a chaotic and emotionally charged delivery, clinicians are often forced to make decisions without the full picture, which can lead to poor outcomes for even the most experienced obstetric teams.Rapid assessment of hemostasis can be the key to successful management of obstetric hemorrhage. However, the viscoelastic testing (VET) systems currently available lack FDA clearance for obstetric use and most provide results that can be hard to interpret. Obstetric teams have had no choice but to rely on devices that don’t quite meet their needs, or to forgo VET testing altogether. That changes now.
The Quantra Hemostasis System with QStat® Cartridge is the only viscoelastic testing platform FDA-cleared for obstetric patients. The Quantra System provides a near real-time, comprehensive, and easy-to-interpret assessment of a patient’s coagulation status in relation to OB-specific reference ranges. This enables clinicians to make faster, more precise decisions and intervene before complications escalate.
Key Features
- Technology trusted in cardiovascular, liver transplant, major orthopedic surgery and trauma, now available to obstetrics teams
- FDA-cleared for peripartum obstetric procedures
- Point-of-need testing – in the lab, OR, or anywhere it’s needed
- Results presented in relation to OB-specific reference ranges
- Easy-to-interpret results in minutes
- 30 seconds of hands-on time
- Automated workflows
Test Parameters1
Comprehensive analysis that helps clinicians identify and correct coagulation deficiencies, hypofibrinogenemia, and other hemorrhage risks that may lead to catastrophic outcomes.
-
CT: Clot time
Results in ~ 5 minutes2 - CS: Clot stiffness
- PCS: Platelet contribution to clot stiffness
-
FCS: Fibrinogen contribution to clot stiffness
Results in ~ 12.5 minutes2 - CSL: Clot stability to lysis True clot lysis measured with and without TXA
Fighting the Maternal Mortality Crisis
Each year, about 14 million women experience postpartum hemorrhage, resulting in about 70,000 maternal deaths globally.
World Health Organization. WHO Postpartum Hemorrhage (PPH) Summit). https://www.who.int/publications/m/item/who-postpartum-haemorrhage-(pph)-summit. Published 29 September 2022. Accessed September 2025.
Approximately 80% of maternal deaths are considered preventable.
American College of Obstetricians and Gynecologists. Maternal Health Awareness Day. ACOG. https://www.acog.org/advocacy/policy-priorities/maternal-mortality-prevention/maternal-health-awareness-day. Published 2025. Accessed September 2025.
In the United States, postpartum hemorrhage accounts for 11.2% of maternal deaths.
Global and regional causes of maternal deaths 2009–20: a WHO systematic analysis. Cresswell, Jenny A et al. The Lancet Global Health, Volume 13, Issue 4, e626 – e634
For more than four decades, maternal deaths linked to hemorrhage have remained unchanged in the U.S., even with medical progress.
Postpartum Hemorrhage and its risk of Maternal deaths in the US. Jayakumaran, Jenani S. et al. American Journal of Obstetrics & Gynecology, Volume 222, Issue 1, S178 – S179
There is a maternal mortality crisis in the United States. We’re here to help healthcare providers in their critical work protecting mothers. Will you lead the effort to improve maternal care?
By adopting the first and only FDA-cleared viscoelastic testing solution for obstetric procedures, hospitals can demonstrate leadership in patient safety, empower care teams with rapid, actionable insights, and set a new standard of excellence in women’s health.
Enable True Standardization and Scale Advanced Hemostasis Care
By offering a single platform with the broadest range of FDA-cleared indications (including cardiovascular, trauma, liver transplant, major orthopedic, and peripartum obstetric procedures), the Quantra System enables true standardization of VET across your entire health system.
With the Quantra System, hospitals can:
- Scale across departments — from Labor & Delivery to the OR to the ICU
- Ensure consistency — more patients receive the same high standard of care
- Accelerate adoption — intuitive design and easy-to- interpret results minimize training needs
- Expand with confidence — backed by HemoSonics’ comprehensive clinical and operational support
Equip Your Team to Address Maternal Bleeding Risks
As the concern for maternal and fetal health outcomes grows, your patients – and your reputation – depend on providing OB teams the best tools available. The Quantra System is the only FDA-cleared VET system designed for peripartum obstetric procedures, helping hospitals deliver safer outcomes and greater peace of mind.
Connect with a HemoSonics expert to get answers or request a demo.